Nuvectis Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Nuvectis Pharma's latest 10-K filing highlights positive Phase 1a results for its lead oncology drug candidate NXP900, while reporting continued significant operating losses and the cessation of NXP800 clinical development.
NASDAQ
Nuvectis Pharma reports its 2024 financial results, highlighting ongoing clinical trials for NXP800 and NXP900 and a recent public offering to bolster its financial position.
NASDAQ
10-K: Nuvectis Pharma 2023 10-K Filing: Details on Capital Structure, Clinical Programs, and Risk Factors
Nuvectis Pharma's 2023 10-K filing outlines the company's financial status, clinical development programs for NXP800 and NXP900, and associated risks.